Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein

Cancer Research

Volumn 60, Issue 24, 2000, Pages 7142-7148

  Slawin, Kevin M ^a   Shariat, Shahrokh F ^a   Nguyen, Cuong ^a   Leventis, Angelos K ^a   Song, Weitao ^a   Kattan, Michael W ^b   Young, Charles Y F ^c   Tindall, Donald J ^c   Wheeler, Thomas M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

3' UNTRANSLATED REGION; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INTRON; LYMPH NODE METASTASIS; LYMPHOBLAST; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING;

ADULT; AGED; ALTERNATIVE SPLICING; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTRONS; KALLIKREINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 0034671481     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994
2. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S. The American College of Surgeons Commission on Cancer and the American Cancer Society
3. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control
4. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
5. Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives
6. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
7. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
8. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay
9. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy
10. Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics
11. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells
12. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy
13. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy
14. RT-PCR for PSA and hK2: Implications for staging and patient management in men undergoing radical prostatectomy
15. Clinical and molecular followup after radical retropubic prostatectomy
16. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer
17. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction
18. Multicenter RT-PCR-PSA clinical trial for preoperative staging of prostate cancer
19. Molecular expression of PSMA mRNA and protein in primary renal tumors
20. Prostate-specific antigen expression by various tumors
21. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: Implications for detection of micrometastases
22. Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells (Letter)
23. Primary structure of a human glandular kallikrein gene
24. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
25. Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer
26. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases
27. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen
28. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
29. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein
30. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
31. Fresh tissue harvest for research from prostatectomy specimens
32. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
33. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species
34. Identification of three new alternate human kallikrein 2 transcripts: Evidence of long transcript and alternative splicing
35. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator
36. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein
37. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo
38. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1
39. The influence of pathological parameters of positive surgical margins on prognosis in patients undergoing radical prostatectomy
40. Disease progression following radical prostatectomy in men with Gleason score 7 tumor
41. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer
42. Radical prostatectomy for clinical stage T1 and T2 prostate cancer
43. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
44. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
45. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages
46. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2
47. Preoperative RT-PCR for PSA mRNA faiIs to predict an increased risk of PSA progression in men undergoing radical prostatectomy
48. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions
49. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood
50. Primers are decisive for sensitivity of PCR